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Abstract
Background: Erectile dysfunction is an emerging risk marker for future cardiovascular disease (CVD) events; however,
evidence on dose response and specific CVD outcomes is limited. This study investigates the relationship between severity
of erectile dysfunction and specific CVD outcomes.
Methods and Findings: We conducted a prospective population-based Australian study (the 45 and Up Study) linking
questionnaire data from 2006–2009 with hospitalisation and death data to 30 June and 31 Dec 2010 respectively for 95,038
men aged $45 y. Cox proportional hazards models were used to examine the relationship of reported severity of erectile
dysfunction to all-cause mortality and first CVD-related hospitalisation since baseline in men with and without previous
CVD, adjusting for age, smoking, alcohol consumption, marital status, income, education, physical activity, body mass index,
diabetes, and hypertension and/or hypercholesterolaemia treatment. There were 7,855 incident admissions for CVD and
2,304 deaths during follow-up (mean time from recruitment, 2.2 y for CVD admission and 2.8 y for mortality). Risks of CVD
and death increased steadily with severity of erectile dysfunction. Among men without previous CVD, those with severe
versus no erectile dysfunction had significantly increased risks of ischaemic heart disease (adjusted relative risk [RR] = 1.60,
95% CI 1.31–1.95), heart failure (8.00, 2.64–24.2), peripheral vascular disease (1.92, 1.12–3.29), ‘‘other’’ CVD (1.26, 1.05–1.51),
all CVD combined (1.35, 1.19–1.53), and all-cause mortality (1.93, 1.52–2.44). For men with previous CVD, corresponding RRs
(95% CI) were 1.70 (1.46–1.98), 4.40 (2.64–7.33), 2.46 (1.63–3.70), 1.40 (1.21–1.63), 1.64 (1.48–1.81), and 2.37 (1.87–3.01),
respectively. Among men without previous CVD, RRs of more specific CVDs increased significantly with severe versus no
erectile dysfunction, including acute myocardial infarction (1.66, 1.22–2.26), atrioventricular and left bundle branch block
(6.62, 1.86–23.56), and (peripheral) atherosclerosis (2.47, 1.18–5.15), with no significant difference in risk for conditions such
as primary hypertension (0.61, 0.16–2.35) and intracerebral haemorrhage (0.78, 0.20–2.97).
Conclusions: These findings give support for CVD risk assessment in men with erectile dysfunction who have not already
undergone assessment. The utility of erectile dysfunction as a clinical risk prediction tool requires specific testing.
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Introduction
Erectile dysfunction is a common health problem that increases
rapidly in prevalence with age. While erectile dysfunction can be a
distressing symptom in itself, there is increasing recognition of its
importance as a risk marker for potentially life-threatening
cardiovascular disease (CVD) events and premature death [1,2].
CVD is the leading cause of morbidity and mortality globally
[3]. Many effective interventions for the primary and secondary
prevention of CVD rely on identifying individuals at increased
risk. Despite the robustness of current risk prediction models, it is
well recognised that a significant proportion of cases of CVD will
occur in individuals without classic risk factors [4]. In men without
known CVD, erectile dysfunction has potential as a sentinel
symptom indicating the presence or increased risk of systemic
CVD [1]. Although the possibility has been less widely investigat-
ed, erectile dysfunction could also serve as a marker of increased
risk of repeated events in men known to have existing CVD.
Currently, evidence on the nature of the relationship of erectile
dysfunction to the risk of developing specific subtypes of CVD is
limited. Previous prospective studies indicate that, among men
without known CVD, those with erectile dysfunction have a
significantly increased risk of grouped CVD outcomes, such as
coronary heart disease, stroke, and peripheral vascular disease,
and all-cause mortality, compared to men without erectile
dysfunction [1,5–8]. However, such evidence is limited by the
following: the predominant use of dichotomised data on erectile
dysfunction status, which precludes evaluation of a dose–response
relationship [1,7–9]; the lack of large-scale evidence on how
erectile dysfunction relates to different subtypes of CVD; the lack
of evidence on how erectile dysfunction relates to CVD in men
with existing CVD, who constitute an important high risk group;
and the relatively small size and selective nature of most of the
studies to date [1,7,8,10].
The aim of this large prospective population-based study is to
investigate the relationship of severity of erectile dysfunction, as a
marker of risk, to a range of CVD outcomes and all-cause
mortality, among men with and without CVD at baseline.
Methods
Data Collection and Definitions
The 45 and Up Study is a large-scale Australian cohort study of
123,775 men and 143,378 women aged 45 y and over, randomly
sampled from the general population of New South Wales (NSW),
Australia. Its methods are described elsewhere [11]. Only men are
included in the study presented here. In brief, from 1 February
2006 to 30 April 2009, individuals from the general population of
NSW joined the study by completing a postal questionnaire and
giving informed consent for follow-up through repeated contact
and population health databases.
Data from study participants have been linked probabilistically
to the NSW Admitted Patient Data Collection, which is a
complete census of all public and private hospital admissions in
NSW. It contains details of admissions in participants from 1 July
2000 to 30 June 2010, including dates of admission and discharge,
the primary reason for admission using the World Health
Organization International Classification of Diseases, 10th revi-
sion—Australian Modification (ICD-10-AM) [12], up to 55
additional clinical diagnoses, and up to 50 operations or
procedures, coded using Australian Classification of Health
Interventions procedure codes [13]. The validity of administrative
coding for specific CVD outcomes varies, ranging from fair to very
good, with kappa scores for agreement between chart review and
recorded diagnoses of 0.6–0.8 [14] and positive predictive values
of 66%–99% [15–18] for acute myocardial infarction, cerebral
infarction, and heart failure. Where misclassification is present, it
is unlikely to be biased by prior knowledge of erectile dysfunction
status and would therefore tend to result in more conservative
estimates of relative risk (RR). Vital status and date of death were
ascertained from the date of recruitment up to 31 December 2010
using linkage to the NSW Registry of Births, Deaths and
Marriages. Death registrations capture all deaths in NSW. Cause
of death information was not available at the time of analysis.
Over the relatively short follow-up period, a small but unknown
number of participants are likely to have moved out of the area.
Although hospitalisations occurring in neighbouring states would
not be captured, these are estimated to make up fewer than 2% of
admissions in NSW residents. Hence, follow-up for hospitalisations
is considered to be ,98% complete among those continuing to
reside in NSW, and loss to follow-up is considered to be minimal.
Quality assurance data show false positive and negative rates for
data linkage of ,0.5% and ,0.1%, respectively.
Baseline questionnaire data included information on socio-
demographic factors, lifestyle, height and weight, medical and
surgical history, functional capacity, physical activity, and sexual
health. The questionnaire for men included a single self-
assessment question on erectile functioning: ‘‘How often are you
able to get and keep an erection that is firm enough for satisfactory
sexual activity?’’, with the response categories being ‘‘always’’,
‘‘usually’’, ‘‘sometimes’’, ‘‘never’’, and ‘‘I would rather not answer
this question’’. The first four categories were used to define erectile
dysfunction as none, mild, moderate, and severe, respectively. This
questionnaire item was based on that used in the Massachusetts
Male Aging Study, which has shown good agreement with the
International Index of Erectile Function (correlation coeffi-
cient = 0.71, kappa= 0.6) [19].
Statistical Methods
At the time of writing, data from 123,750 male 45 and Up
Study participants (99.98%) had been linked to data on hospital
admissions and deaths. Among these, men who were missing data
(n=4,264; 3.4%), who chose not to answer the question on erectile
dysfunction (n=11,034; 8.9%), or whose records had linkage
errors (n=25; 0.02%) were excluded. Because cancer and its
treatment may lead to erectile dysfunction and affect future
survival and CVD risk, those with a self-reported history of
prostatectomy and/or cancer other than melanoma and skin
cancer (n=13,389; 10.8%) were also excluded. We did not have
specific data on other procedures that can result in erectile
dysfunction, such as pelvic irradiation, abdomino-pelvic resection,
and low anterior resection; however, as these are largely used as
treatments for cancer, individuals with these interventions would
have been mostly excluded from the analyses. Following exclu-
sions, data were available on 95,038 men for the main analyses.
The main CVD outcome was defined as the first hospitalisation
following recruitment into the 45 and Up Study with a primary
diagnosis of CVD at discharge, based on ICD-10-AM three-character
codes I00–I99, G45, and G46. Diagnoses were grouped consistent
with the NSW 2010 health report [20] (see Figure 1), and were also
examined individually for diagnoses for which at least 50 events were
reported in men with no previous CVD. In the analyses of incident
CVD hospitalisation since baseline, eligible men contributed person-
years from the date of recruitment until the CVD admission date,
date of death, or end of follow-up (30 June 2010), whichever was the
earliest. In the analysis of all-cause mortality, eligible men contributed
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person-years from recruitment until death or end of follow-up (31
December 2010), whichever was the earliest.
Estimates of incident CVD hospitalisation rates since baseline
and 95% confidence intervals (95% CIs) were calculated for the
different levels of erectile dysfunction at baseline, age-standardised
to the 2006 NSW population, in 5-y age groups, using the direct
method [21]. Hazard ratios (RRs) for specific CVD outcomes, all
CVD, and all-cause mortality according to erectile dysfunction at
baseline were estimated using Cox regression modelling, using age
as the underlying time variable to finely adjust for age. Each
outcome of interest was considered as an end point in the model,
except where used for censoring. RRs and 95% CIs take account
of age (the underlying time variable), adjusting where appropriate
for tobacco smoking (current, past, never), alcohol consumption (0,
1–14, $15 drinks/week), marital status (living alone [single/
widowed/divorced], living with a partner [married/living with a
partner]), annual household pre-tax income (in Australian dollars:
,$20,000, $20,000–$39,999, $40,000–$69,999, $$70,000), edu-
cation (secondary school incomplete, secondary school graduation,
certificate or diploma, university graduation), tertiles of physical
activity (based on number of weekly sessions, weighted for intensity
[22]), body mass index (BMI, based on self-reported height and
weight, which has been shown to correlate well with that based on
measured values in this population [r=0.95], with a relatively
small mean difference in values [23]) (15.0–18.49, 18.5–24.99,
25.0–29.99, $30.0 kg/m2), self-reported doctor-diagnosed diabe-
tes (yes, no), current treatment for hypertension (yes, no), and
current treatment for hypercholesterolaemia (yes, no). Missing
values for covariates were included in the models as separate
categories. No material differences in the main exposure–outcome
relationships (ischaemic heart disease and all CVD) were observed
when BMI, alcohol consumption, and physical activity were
modelled as continuous variables (Table S1). Sensitivity analyses
modelling the effect of assuming that men who stated that they
would rather not answer the question on erectile dysfunction had
severe erectile dysfunction demonstrated that the main findings
did not vary materially according to this assumption (Table S2).
Analyses of CVD outcomes were stratified throughout by
previous CVD status. Previous CVD was defined as self-reported
heart disease, stroke, or blood clot (including peripheral blood
clots) on the baseline questionnaire, or a hospital admission in the
6 y prior to study entry with a CVD diagnosis code in any
diagnostic field or a CVD-related procedure code in any
procedure code field (Table 1).
The proportionality assumption was verified by plotting the
Schoenfeld residuals against the time variable in each model, with a
stratified form used where covariates displayed non-proportionality
of hazards. Tests for trend were performed by modelling erectile
dysfunction as an ordinal variable. To test for interaction between
erectile dysfunction categories and previous CVD, the likelihood-
ratio test was used, stratified by age because of strong age–previous
CVD relationships, to compare the model with and without the
interaction term. The weighted least-squares method was used to
test for heterogeneity in the RR for dichotomised erectile
dysfunction (severe/moderate versus mild/none) in different study
subgroups. All analyses were carried out using SAS version 9.3 [24].
All statistical tests were two-sided, using a significance level of 5%.
Ethical approval for the study was provided by the NSWPopulation
and Health Services Research Ethics Committee (2010/05/234).
Results
The study population ranged in age from 45 to 106 y, with a
mean of 62.0 y (standard deviation 10.5 y). Erectile dysfunction
increased steeply with age, with a prevalence of severe erectile
dysfunction of 2.2% at age 45–54 y, 6.8% at age 55–64 y, 20.2%
at age 65–74 y, 50.0% at age 75–84 y, and 75.4% at age $85 y.
Overall, the prevalence of severe erectile dysfunction was higher in
smokers and in men with lower incomes, lower consumption of
alcohol, lower education, and/or single/widower marital status,
compared to other men (Table 1). Severe erectile dysfunction was
also more common in men who had been diagnosed with diabetes
and/or CVD in the past and in those who were receiving
treatment for hypertension and/or hypercholesterolaemia, com-
pared to men without these risk factors.
Median (mean) follow-up time for the cohort was 1.9 (2.2) y for
CVD hospitalisation and 2.2 (2.8) y for mortality; over this time,
7,855 incident hospital admissions with a primary diagnosis of
CVD and 2,304 deaths occurred. The age-standardised incidences
of all-cause mortality and of hospitalisation for ischaemic heart
disease, heart failure, peripheral vascular disease, ‘‘other’’ CVD,
and all CVD combined generally increased with increasing
severity of erectile dysfunction and generally were higher for
men with prior CVD at baseline, compared to men without prior
CVD (Figure 1).
The adjusted RRs of ischaemic heart disease, heart failure, stroke,
peripheral vascular disease, ‘‘other’’ CVD, and all CVD combined
increased significantly with increasing severity of baseline erectile
dysfunction, in men with and without a past history of CVD
(Figure 2; p[trend],0.001 for all comparisons, except stroke and
other CVD in men without previous CVD, where p[trend] = 0.008
and 0.04, respectively). These RRs varied according to the type of
CVD outcome examined, with greater RRs for heart failure than
for other grouped CVD outcomes (Figure 2). The relationship of
severity of erectile dysfunction to CVD outcomes did not vary
significantly according to history of CVD prior to baseline
(p[interaction] for all strata .0.05, except for stroke, where
p[interaction] = 0.02). Men with severe erectile dysfunction had
approximately a doubling in the risk of death during follow-up
compared to men without erectile dysfunction (Figure 2), regardless
of past CVD history. The relation of erectile dysfunction to
subsequent CVD events did not vary materially according to
duration of follow-up (i.e., ,2 y versus $2 y; Table S3).
Among men with no previous history of CVD, significant trends
of increasing hospitalisation risk for specific ICD-10-AM primary
diagnostic codes with increasing erectile dysfunction were seen for
angina pectoris, acute myocardial infarction, chronic ischaemic
heart disease, atrioventricular and left bundle branch block, heart
failure, and (peripheral) atherosclerosis (Table 2). No clear patterns
of increasing risk were observed for conditions such as pulmonary
embolism, dysrhythmias, intracerebral haemorrhage, aortic aneu-
rysm, phlebitis and thrombophlebitis, and haemorrhoids. Findings
were broadly similar for men with previous CVD (Table 3). There
were fewer than 50 admissions for cardiomyopathy (I42) among
men without previous CVD, so the findings are not included in
Table 2; however, there were more than 50 events for men with
previous CVD, with noteworthy findings: RRs (95% CIs) for this
outcome were 2.38 (0.95–5.97), 3.61 (1.47–8.84), and 3.21 (1.23–
8.35) for mild, moderate, and severe erectile dysfunction versus no
dysfunction (p[trend] = 0.02).
When categorised as a dichotomous variable (severe/moderate
versus no/mild erectile dysfunction), the relationship of erectile
dysfunction to all CVD combined was significantly attenuated in
those reporting greater alcohol consumption and in those without
diabetes, but did not vary significantly (i.e., p [heterogeneity] was
not significant) by age, smoking, education, income, treatment for
hypertension, and a range of other personal characteristics
(Figure 3). When adjusted only for age, the relationship of erectile
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Figure 1. Age-standardised rates (per 1,000 person-years) of grouped CVD hospitalisations since baseline and all-cause mortality
by degree of erectile dysfunction and previous CVD history, directly age-standardised to the 2006 New South Wales population. All
CVD includes ICD-10-AM diagnosis codes I00–I99, G45, and G46; ischaemic heart disease includes I20–I25; peripheral vascular disease (PVD) includes
I70–I74; stroke includes I60–I69, G45, and G46; heart failure is I50; and other CVD is all CVDs except those listed above. Vertical lines indicate 95% CIs.
doi:10.1371/journal.pmed.1001372.g001
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dysfunction to all-cause mortality appeared stronger in younger
men (Figure 4). However, this difference was not apparent
following more comprehensive adjustment for potential confound-
ing factors (p[heterogeneity by age] = 0.2; Figure 4). The
association between erectile dysfunction and all-cause mortality
did not vary significantly according to any of the factors examined,
apart from BMI, where the relationship showed non-systematic
variation in the RRs, of borderline statistical significance
(p[heterogeneity by BMI]= 0.04; Figure 4).
Discussion
In this large population-based prospective cohort study, the risk
of hospitalisation for CVD increased progressively with the self-
reported severity of erectile dysfunction in men without and with
known CVD at baseline, and this pattern was present after
adjusting for established risk factors for CVD. Compared to men
without erectile dysfunction, men with severe erectile dysfunction
had RRs of approximately 1.5 to 2.0 for ischaemic heart disease,
peripheral vascular disease, combined CVD events, and all-cause
mortality, and even greater point estimates for risk (albeit with
wide confidence intervals) for conditions such as heart failure and
atrioventricular and left bundle branch block.
The current study is an order of magnitude larger than any
previous prospective study of erectile dysfunction and CVD known
to us, and provides the strongest evidence to date of a relationship
of increasing CVD risk with increasing self-reported severity of
erectile dysfunction [7,8,25]. Our results lend strong support to
previous studies, which have found that among men without
known CVD at baseline, those with moderate or severe erectile
dysfunction have increased risks of a subsequent CVD event
[1,7,8,10,25], including ischaemic heart disease [1,5,7,8,10],
Figure 2. Relative risk of grouped CVD admissions and all-cause mortality since baseline, according to severity of erectile
dysfunction at baseline. *RR adjusted for age only. #RR adjusted for age, tobacco smoking, alcohol consumption, marital status, income,
education, physical activity, BMI, diabetes, and current treatment for hypertension and hypercholesterolaemia. RRs are plotted on a log scale and are
represented with squares with areas inversely proportional to the variance of the logarithm of the RR, providing an indication of the amount of
statistical information available; 95% CIs are indicated by horizontal lines. ED, erectile dysfunction, PVD, peripheral vascular disease.
doi:10.1371/journal.pmed.1001372.g002
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stroke [1,7,8,10], and peripheral vascular disease [6,10], as well as
all-cause mortality [7,26], compared to men with mild or no
erectile dysfunction, based on data from over 30,000 participants
in relevant prospective studies (,15,000 in prospective popula-
tion-based studies) [7,8]. Although heart failure is often a
consequence of ischaemic heart disease, our finding on the
relationship between severity of erectile dysfunction and future
admissions for heart failure is, to our knowledge, novel and
warrants further investigation, given that this condition is common
and results in a considerable burden of disease. Similarly, we were
unable to locate any previous prospective studies demonstrating
the increased risks of chronic ischaemic heart disease and
atrioventricular and left bundle branch block with increasing
levels of erectile dysfunction.
Erectile dysfunction per se is unlikely to be a major independent
cause of CVD, and is best considered as a risk marker rather than
a risk factor for CVD. That is, it is likely to serve as an indicator, or
‘‘biomarker’’, of the severity of underlying pathological processes
such as atherosclerosis and endothelial dysfunction. Hence, the
study presented here does not aim to investigate erectile
dysfunction as an independent cause of CVD. It quantifies the
gradient in CVD risk with increasing degrees of erectile
dysfunction because this relationship is likely to inform the
potential usefulness of erectile dysfunction as a risk marker in
predicting events and in discriminating at what level clinical
concerns should be raised. Additional CVD risk factors are
adjusted for, where possible, with the aim of demonstrating how
well the marker predicts risk above and beyond these additional
factors.
Although the pathophysiology of erectile dysfunction is multi-
factorial and includes arterial, neurogenic, hormonal, cavernosal,
iatrogenic, and psychogenic causes [27], it is now widely accepted
that erectile dysfunction is predominantly due to underlying
vascular causes, particularly atherosclerosis [28]. Endothelial
dysfunction is considered a key pathophysiological cause of erectile
dysfunction and CVD [28]. The normal function of the corpus
cavernosum is highly dependent on intact endothelium-dependent
relaxation, which potentially explains why erectile dysfunction
Table 2. Relative risk (95% CI) of incident CVD-related hospital admission since baseline among men with no previous history of
CVD by ICD-10-AM diagnosis code, according to degree of erectile dysfunction (ED).
Outcome (ICD-10-AM Code)
Number of Events
by ED: None/Mild/
Mod/Severe Adjusted RR (95% CI) for Outcome, according to ED Severity
p-Value
Trenda
None Mild Moderate Severe
Transient cerebral ischaemic attacks and
related syndromes (G45)
50/27/46/25 1.00 0.78 (0.49–1.26) 1.67 (1.06–2.61) 1.04 (0.58–1.87) 0.3
Essential (primary) hypertension (I10) 11/6/9/4 1.00 0.72 (0.26–1.98) 1.17 (0.44–3.07) 0.61 (0.16–2.35) 0.7
Angina pectoris (I20) 160/105/108/86 1.00 0.94 (0.73–1.21) 1.25 (0.96–1.62) 1.48 (1.08–2.02) 0.009
Acute myocardial infarction (I21) 143/111/104/108 1.00 1.11 (0.86–1.43) 1.30 (0.99–1.70) 1.66 (1.22–2.26) 0.001
Chronic ischaemic heart disease (I25) 120/107/98/83 1.00 1.25 (0.96–1.63) 1.46 (1.09–1.95) 1.74 (1.25–2.42) ,0.001
Pulmonary embolism (I26) 35/20/12/21 1.00 0.85 (0.48–1.49) 0.65 (0.32–1.31) 1.61 (0.83–3.14) 0.5
Other diseases of pericardium (I31) 14/9/3/5 1.00 1.17 (0.49–2.80) 0.52 (0.13–2.04) 0.93 (0.24–3.69) 0.7
Nonrheumatic aortic valve disorders (I35) 9/9/16/15 1.00 1.12 (0.44–2.85) 1.97 (0.82–4.76) 1.91 (0.72–5.02) 0.08
Atrioventricular and left bundle branch
block (I44)
4/3/15/16 1.00 0.94 (0.20–4.28) 5.32 (1.60–17.67) 6.62 (1.86–23.56) ,0.001
Paroxysmal tachycardia (I47) 24/28/16/10 1.00 1.79 (1.02–3.12) 1.47 (0.75–2.88) 1.54 (0.66–3.61) 0.2
Atrial fibrillation and flutter (I48) 100/70/77/59 1.00 0.93 (0.68–1.27) 1.22 (0.88–1.68) 1.21 (0.82–1.78) 0.2
Other cardiac arrhythmias (I49) 28/10/11/18 1.00 0.44 (0.21–0.91) 0.53 (0.25–1.15) 0.88 (0.41–1.90) 0.6
Heart failure (I50) 4/19/23/46 1.00 5.19 (1.75–15.45) 5.37 (1.78–16.16) 8.00 (2.64–24.23) ,0.001
Intracerebral haemorrhage (I61) 7/4/14/5 1.00 0.64 (0.18–2.24) 2.08 (0.75–5.79) 0.78 (0.20–2.97) 0.7
Cerebral infarction (I63) 23/25/40/27 1.00 1.30 (0.73–2.32) 2.08 (1.19–3.64) 1.31 (0.67–2.54) 0.2
Stroke, not specified as haemorrhage or
infarction (I64)
14/11/17/11 1.00 0.91 (0.40–2.03) 1.39 (0.64–3.05) 0.94 (0.36–2.40) 0.7
Atherosclerosis (I70)b 14/13/19/30 1.00 0.96 (0.44–2.06) 1.39 (0.67–2.89) 2.47 (1.18–5.15) 0.009
Aortic aneurysm and dissection (I71) 10/9/13/19 1.00 0.79 (0.32–1.97) 0.96 (0.40–2.30) 1.42 (0.59–3.43) 0.3
Phlebitis and thrombophlebitis (I80) 28/12/15/11 1.00 0.65 (0.33–1.29) 1.13 (0.57–2.23) 1.30 (0.57–2.97) 0.5
Varicose veins of lower extremities (I83) 52/21/17/14 1.00 0.68 (0.40–1.13) 0.87 (0.49–1.57) 1.36 (0.68–2.74) 0.8
Haemorrhoids (I84) 256/141/74/32 1.00 0.99 (0.80–1.22) 0.91 (0.69–1.20) 0.84 (0.56–1.27) 0.4
Hypotension (I95) 6/10/13/12 1.00 1.72 (0.61–4.85) 2.06 (0.72–5.86) 2.03 (0.66–6.28) 0.2
RR adjusted for age, tobacco smoking, alcohol consumption, marital status, income, education, physical activity, BMI, diabetes, and current treatment for hypertension
and hypercholesterolaemia. ICD-10-AM three-character codes with at least 50 events among men with no previous history of CVD are reported.
CVD, cardiovascular disease; ED, erectile dysfunction; ICD-10-AM, World Health Organization International Classification of Diseases 10th revision – Australian
Modification; RR, relative risk; 95% CI, 95% confidence interval.
ap-Values for trend in risk of CVD outcome across the different categories of ED.
bRefers to predominantly peripheral atherosclerosis.
doi:10.1371/journal.pmed.1001372.t002
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may precede other clinical manifestations of systemic atheroscle-
rosis. It has also been hypothesized that progressive occlusive/
atherosclerotic disease might manifest itself earlier in smaller blood
vessels, such as those in the penis, than in larger blood vessels [29].
The observed relationship of erectile dysfunction to subsequent
hospitalisation for atherosclerotic conditions such as angina [1],
acute myocardial infarction [1], ischaemic stroke, and peripheral
vascular disease, over and above known CVD risk factors, is
therefore biologically plausible. A large proportion of deaths in
older men are attributable to CVD, so the relationship of erectile
dysfunction to CVD is likely to be an important contributor to the
relationship of erectile dysfunction to all-cause mortality.
The mechanisms underlying the relationship of erectile
dysfunction to hospitalisation for the other CVD diagnoses
observed in this study require further exploration. Erectile
dysfunction is extremely common in men with heart failure [30],
and since a large proportion of heart failure is undiagnosed,
particularly at its early stages [31], erectile dysfunction may serve
as an early marker of occult heart failure that subsequently
manifests itself and necessitates treatment in hospital. Conditions
categorised as atrioventricular and left bundle branch block are
likely to be multifactorial and include ischaemic heart disease as
well as fibrotic degeneration of the cardiac conducting system
related to primary causes or secondary to ischaemic heart disease
and/or cardiomyopathies. The large sample size permitted a large
number of comparisons to be performed, which raises type 1 error
as a possible explanation for some relationships identified, but the
lack of a clear relationship between erectile dysfunction and
certain other CVD diagnoses (e.g., pulmonary embolism) suggests
a degree of specificity in its potential to predict disease.
The relationship of severity of erectile dysfunction to the
different types of CVD was similar for those with and without a
prior history of CVD, indicating that erectile dysfunction remains
a risk marker even in those with known CVD. Men with existing
CVD should, theoretically, already be receiving maximal second-
ary preventative therapy, so the clinical utility of markers of
increased risk of recurrent events is open to question. Since in
reality there are consistent and often large gaps between
recommended treatment and actual practice for those with
existing CVD [32], markers of increased risk of recurrent events
Table 3. Relative risk of incident CVD-related hospital admission since baseline among men with previous history of CVD by ICD-
10-AM diagnosis code, according to degree of erectile dysfunction.
Outcome (ICD-10-AM Code)
Number of Events
by ED: None/Mild/
Mod/Severe Adjusted RR (95% CI) for Outcome, according to ED Severity
p-Value
Trenda
None Mild Moderate Severe
Transient cerebral ischaemic attacks
and related syndromes (G45)
28/37/51/116 1.00 1.06 (0.64–1.75) 0.88 (0.54–1.44) 0.98 (0.60–1.59) 1.0
Essential (primary) hypertension (I10) 5/9/9/17 1.00 1.57 (0.52–4.75) 1.29 (0.41–4.05) 1.61 (0.51–5.09) 0.9
Angina pectoris (I20) 165/205/289/442 1.00 1.24 (1.00–1.52) 1.44 (1.17–1.77) 1.71 (1.39–2.10) ,0.001
Acute myocardial infarction (I21) 95/74/119/261 1.00 0.75 (0.55–1.03) 0.88 (0.66–1.17) 1.20 (0.90–1.59) 0.05
Chronic ischaemic heart disease (I25) 130/148/234/317 1.00 1.16 (0.92–1.48) 1.62 (1.29–2.04) 1.81 (1.43–2.30) ,0.001
Pulmonary embolism (I26) 22/20/25/36 1.00 0.82 (0.44–1.53) 0.69 (0.37–1.29) 0.59 (0.31–1.12) 0.07
Other diseases of pericardium (I31) 3/5/7/8 1.00 1.71 (0.40–7.25) 1.93 (0.47–8.00) 1.56 (0.34–7.18) 0.9
Nonrheumatic aortic valve disorders (I35) 10/27/33/49 1.00 2.68 (1.28–5.61) 2.40 (1.12–5.12) 2.18 (1.00–4.73) 0.2
Atrioventricular and left bundle branch
block (I44)
8/8/23/70 1.00 0.73 (0.27–1.98) 1.25 (0.53–2.93) 2.00 (0.88–4.55) 0.01
Paroxysmal tachycardia (I47) 20/33/27/50 1.00 1.73 (0.98–3.05) 1.10 (0.59–2.04) 1.48 (0.80–2.73) 0.4
Atrial fibrillation and flutter (I48) 143/127/155/262 1.00 0.91 (0.72–1.17) 0.95 (0.74–1.21) 1.18 (0.92–1.52) 0.2
Other cardiac arrhythmias (I49) 13/22/46/62 1.00 1.60 (0.79–3.21) 2.46 (1.27–4.77) 2.03 (1.02–4.03) 0.1
Heart failure (I50) 18/38/113/357 1.00 1.76 (1.00–3.11) 2.98 (1.78–5.00) 4.40 (2.64–7.33) ,0.001
Intracerebral haemorrhage (I61) 3/10/16/27 1.00 2.82 (0.77–10.32) 3.28 (0.92–11.64) 3.35 (0.93–12.09) 0.1
Cerebral infarction (I63) 22/17/59/106 1.00 0.62 (0.33–1.18) 1.39 (0.83–2.34) 1.45 (0.86–2.44) 0.02
Stroke, not specified as haemorrhage or
infarction (I64)
8/13/27/67 1.00 1.39 (0.57–3.41) 1.54 (0.67–3.54) 1.95 (0.86–4.42) 0.1
Atherosclerosis (I70)b 13/30/65/138 1.00 2.00 (1.04–3.86) 2.97 (1.61–5.50) 3.98 (2.16–7.34) ,0.001
Aortic aneurysm and dissection (I71) 13/19/32/58 1.00 1.20 (0.59–2.45) 1.30 (0.66–2.56) 1.44 (0.73–2.83) 0.3
Phlebitis and thrombophlebitis (I80) 11/5/20/34 1.00 0.47 (0.16–1.36) 1.42 (0.63–3.19) 1.62 (0.70–3.74) 0.1
Varicose veins of lower extremities (I83) 10/25/24/24 1.00 2.71 (1.28–5.72) 2.56 (1.17–5.59) 2.41 (1.04–5.58) 0.1
Haemorrhoids (I84) 132/106/100/65 1.00 1.07 (0.82–1.39) 1.19 (0.90–1.58) 0.83 (0.58–1.19) 0.7
Hypotension (I95) 6/12/37/81 1.00 1.47 (0.55–3.93) 2.51 (1.03–6.07) 2.75 (1.14–6.62) 0.01
RR adjusted for age, tobacco smoking, alcohol consumption, marital status, income, education, physical activity, BMI, diabetes, and current treatment for hypertension
and hypercholesterolaemia. ICD-10-AM three-character codes with at least 50 events in men with no previous history of CVD are reported.
ap-Values for trend in risk of CVD outcome across the different categories of ED.
bRefers to predominantly peripheral atherosclerosis.
ED, erectile dysfunction.
doi:10.1371/journal.pmed.1001372.t003
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Figure 3. Relative risk of any CVD admission since baseline among men with severe/moderate erectile dysfunction (ED) compared
to those with mild/no erectile dysfunction (no ED), in a range of population subgroups, among men with no previous CVD. *RR
adjusted for age. #RR adjusted for age, tobacco smoking, alcohol consumption, marital status, income, education, physical activity (PA), BMI,
diabetes, and current treatment for hypertension and hypercholesterolaemia where appropriate. RRs are represented with squares with areas
inversely proportional to the variance of the logarithm of the RR, providing an indication of the amount of statistical information available. 95% CIs
are indicated by horizontal lines. The vertical dotted line represents the overall RR of CVD events in men with moderate/severe erectile dysfunction
versus no/mild erectile dysfunction. Defacto, living with a partner.
doi:10.1371/journal.pmed.1001372.g003
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Figure 4. Relative risk of all-cause mortality among men with severe/moderate erectile dysfunction (ED) compared to those with
mild/no erectile dysfunction (no ED), in a range of population subgroups, among men with no previous CVD. *RR adjusted for age.
#RR adjusted for age, tobacco smoking, alcohol consumption, marital status, income, education, physical activity (PA), BMI, diabetes, and current
treatment for hypertension and hypercholesterolaemia where appropriate. RRs are represented with squares with areas inversely proportional to the
variance of the logarithm of the RR, providing an indication of the amount of statistical information available. 95% CIs are indicated by horizontal
lines. The vertical dotted line represents the overall RR of all-cause mortality in men with moderate/severe erectile dysfunction versus no/mild erectile
dysfunction. Defacto, living with a partner.
doi:10.1371/journal.pmed.1001372.g004
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could potentially be useful for improving secondary prevention of
CVD. However, the findings reported here for individuals with a
prior history of CVD should be interpreted with caution, since a
number of treatments for CVD increase the risk of erectile
dysfunction.
Using data from the cohort prior to exclusions, 16% of men
aged 50–59 y, 34% of men aged 60–69 y, and 60% of men aged
$70 y reported moderate or severe erectile dysfunction; this
compares with 11%, 31%, and 68% affected in the same age
groups in a representative population-based telephone survey of
Australian men [33]. Hence, although representativeness is not
necessary for valid and reliable estimates of RR from within-
cohort comparisons [34], the degree of erectile dysfunction within
the cohort is broadly similar to that in the general population.
Our study included men aged 45 y and over and, following
adjustment for a wide range of potential confounding factors,
found that the relationship of erectile dysfunction to CVD and to
all-cause mortality did not differ significantly for men of different
ages. Two previous studies found stronger erectile dysfunction–
CVD relationships in younger than in older men [5,35],
particularly in men under 40 y [35], while another found
consistent relationships across age groups [36]. In our study, the
increased risk of CVD hospitalisation in men with moderate/
severe versus mild/no erectile dysfunction was more pronounced
in men with diabetes. Other evidence on this is heterogeneous,
with previous studies in men with diabetes suggesting slightly lesser
and greater erectile-dysfunction-associated risk of CVD compared
to studies including the broader population [7,10]. The attenu-
ation in the erectile dysfunction–CVD relationship with increasing
alcohol consumption could potentially be explained by the fact
that heavy drinkers may have erectile dysfunction for reasons
other than underlying CVD.
In studies of the relationship between risk factors and disease,
short follow-up time is often seen as a limitation, particularly if
there are issues with reverse causality, where the presence of
disease can influence the risk factor itself. In contrast, where a risk
marker is being considered, with the aim of measuring something
that relates to the presence and severity of underlying disease,
short follow-up time is often desirable, as is the case here. Provided
there are sufficient numbers of health events, a short follow-up
time allows quantification of the relationship of the risk marker to
the immediate risk of disease. In particular, because erectile
dysfunction status is likely to change increasingly with time since
baseline, longer follow-up might lead to reduced accuracy of
prediction.
Several study limitations may potentially influence the inter-
pretation of results in our study. (i) While erectile dysfunction at
baseline was measured using a single validated question, the
duration of dysfunction was unknown. (ii) Data on potential
confounding factors were mostly based on self-report. (iii)
Measured data on CVD risk factors such as blood pressure and
blood lipids were not available. (iv) Information on use of
medications, including CVD medications and those used to treat
erectile dysfunction, such as phosphodiesterase type 5 inhibitors,
was not available for this study. Use of phosphodiesterase type 5
inhibitors is likely to be relatively uncommon in Australia, with the
most relevant survey showing that 5% of men aged 40 y and over
reported ever having received medical treatment for erectile
dysfunction [33]. Given that users may have been misclassified as
having no erectile dysfunction, and that use of phosphodiesterase
type 5 inhibitors does not appear to influence the risk of
myocardial infarction or cardiovascular death [37], this bias, if it
were present, would tend to lead to conservative estimates of RR.
(v) Administrative data were used for CVD hospitalisation end
points—these are independent and virtually complete for cohort
members, with fair to very good validity, but were not confirmed
individually by chart review or other methods. (vi) Power was
limited for some subtypes of CVD. (vii) Finally, we cannot exclude
the possibility that the findings presented here are affected by
unmeasured confounding. The fact that a range of disease
processes, apart from those related to erectile dysfunction, may
lead to a CVD event should also be considered.
The findings of this study highlight the need to consider erectile
dysfunction in relation to the risk of a wide range of CVDs that
extends beyond ischaemic heart disease and stroke and includes
conditions such as heart failure and conduction disorders. They
also provide evidence that CVD risk is elevated across a spectrum
of severity of erectile dysfunction and that men with mild or
moderate erectile dysfunction should be considered at increased
risk, in addition to those with severe disease. Nevertheless, this
does not translate automatically into utility as part of a clinical risk
score, such as using erectile dysfunction in addition to the
Framingham score [36]. Rather, the findings provide general
support for the Princeton consensus [29] that men with erectile
dysfunction require assessment for CVD risk, while the quantita-
tive ability of erectile dysfunction to predict risk in the clinical
setting, over and above clinically measured risk factors, requires
specific testing.
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Editors’ Summary
Background. Erectile dysfunction is the medical term used
when a man is unable to achieve or sustain an erection of his
penis suitable for sexual intercourse. Although a sensitive
topic that can cause much embarrassment and distress,
erectile dysfunction is very common, with an estimated 40%
of men over the age of 40 years experiencing frequent or
occasional difficulties. The most common causes of erectile
dysfunction are medications, chronic illnesses such as
diabetes, and drinking too much alcohol. Stress and mental
health problems can also cause or worsen erectile dysfunc-
tion. There is also increasing evidence that erectile dysfunc-
tion may actually be a symptom of cardiovascular disease—a
leading cause of death worldwide—as erectile dysfunction
could indicate a problem with blood vessels or poor blood
flow commonly associated with cardiovascular disease.
Why Was This Study Done? Although previous studies
have suggested that erectile dysfunction can serve as a
marker for cardiovascular disease in men not previously
diagnosed with the condition, few studies to date have
investigated whether erectile dysfunction could also indicate
worsening disease in men already diagnosed with cardio-
vascular disease. In addition, previous studies have typically
been small and have not graded the severity of erectile
dysfunction or investigated the specific types of cardiovas-
cular disease associated with erectile dysfunction. In this
large study conducted in Australia, the researchers investi-
gated the relationship of the severity of erectile dysfunction
with a range of cardiovascular disease outcomes among men
with and without a previous diagnosis of cardiovascular
disease.
What Did the Researchers Do and Find? The researchers
used information from the established 45 and Up Study, a
large cohort study that includes 123,775 men aged 45 and
over, selected at random from the general population of
New South Wales, a large region of Australia. A total of
95,038 men were included in this analysis. The male
participants completed a postal questionnaire that included
a question on erectile functioning, which allowed the
researchers to define erectile dysfunction as none, mild,
moderate, or severe. Using information captured in the New
South Wales Admitted Patient Data Collection—a complete
record of all public and private hospital admissions,
including the reasons for admission and the clinical
diagnosis—and the government death register, the research-
ers were able to determine health outcomes of all study
participants. They then used a statistical model to estimate
hospital admissions for cardiovascular disease events for
different levels of erectile dysfunction.
The researchers found that the rates of severe erectile
dysfunction among study participants were 2.2% for men
aged 45–54 years, 6.8% for men aged 55–64 years, 20.2% for
men aged 65–74 years, 50.0% for men aged 75–84 years, and
75.4% for men aged 85 years and over. During the study
period, the researchers recorded 7,855 hospital admissions
related to cardiovascular disease and 2,304 deaths. The
researchers found that among men without previous
cardiovascular disease, those with severe erectile dysfunction
were more likely to develop ischemic heart disease (risk
1.60), heart failure (risk 8.00), peripheral vascular disease (risk
1.92), and other causes of cardiovascular disease (risk 1.26)
than men without erectile dysfunction. The risks of heart
attacks and heart conduction problems were also increased
(1.66 and 6.62, respectively). Furthermore, the combined risk
of all cardiovascular disease outcomes was 1.35, and the
overall risk of death was also higher (risk 1.93) in these men.
The researchers found that these increased risks were similar
in men with erectile dysfunction who had previously been
diagnosed with cardiovascular disease.
What Do These Findings Mean? These findings suggest
that compared to men without erectile dysfunction, there is
an increasing risk of ischemic heart disease, peripheral
vascular disease, and death from all causes in those with
increasing degrees of severity of erectile dysfunction. The
authors emphasize that erectile dysfunction is a risk marker
for cardiovascular disease, not a risk factor that causes
cardiovascular disease. These findings add to previous
studies and highlight the need to consider erectile dysfunc-
tion in relation to the risk of different types of cardiovascular
disease, including heart failure and heart conduction
disorders. However, the study’s reliance on the answer to a
single self-assessed question on erectile functioning limits
the findings. Nevertheless, these findings provide useful
information for clinicians: men with erectile dysfunction are
at higher risk of cardiovascular disease, and the worse the
erectile dysfunction, the higher the risk of cardiovascular
disease. Men with erectile dysfunction, even at mild or
moderate levels, should be screened and treated for
cardiovascular disease accordingly.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001372.
N Wikipedia defines erectile dysfunction (note that Wikipedia
is a free online encyclopedia that anyone can edit)
N MedlinePlus also has some useful patient information on
erectile dysfunction
N The Mayo Clinic has patient-friendly information on the
causes of, and treatments for, erectile dysfunction, and also
includes information on the link with cardiovascular
disease
N The National Heart Foundation of Australia provides
information for health professionals, patients, and the
general public about how to prevent and manage
cardiovascular disease, including assessment and
management of cardiovascular disease risk
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